Black Diamond Therapeutics (BDTX) to Post Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.18) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Trading Up 2.7%

BDTX stock opened at $1.74 on Tuesday. The firm’s 50-day moving average is $1.87 and its two-hundred day moving average is $2.29. The company has a market capitalization of $99.42 million, a price-to-earnings ratio of -2.25 and a beta of 3.28. Black Diamond Therapeutics has a 52 week low of $1.60 and a 52 week high of $4.94.

Analyst Ratings Changes

BDTX has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a research report on Friday, May 22nd. Weiss Ratings lowered Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, July 13th. BTIG Research lifted their price target on Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, HC Wainwright restated a “buy” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Black Diamond Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. grew its position in Black Diamond Therapeutics by 152.5% during the first quarter. Invesco Ltd. now owns 45,989 shares of the company’s stock worth $71,000 after buying an additional 27,777 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Black Diamond Therapeutics in the 1st quarter worth approximately $84,000. American Century Companies Inc. acquired a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $30,000. Prudential Financial Inc. acquired a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $32,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Black Diamond Therapeutics during the second quarter valued at approximately $343,000. Institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.